Immune Thrombocytopenic PurpuraNCT07059910
Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment
An observational study of Immune Thrombocytopenic Purpura and Thyroid Disorders, run by Assiut University.
Trial summary
Prevalence of thyroid disorders in patients with immune thrombocytopenic purpura and its impact on treatment Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Immune Thrombocytopenic Purpura, Thyroid Disorders
- What is being tested?
- Search for thyroid disorders, Laboratory test and Steroid and eltrombopage
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- Jul 2025to 15 Aug 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: prospective cross sectional study
Who may be able to join
- ITP patients will be classified as newly diagnosed, persistent and chronic based on duration less than 3 months, 3-12 months, and more than 12 months respectively.
- refractory ITP patients.
Who cannot join
- patients with history of thyroidectomy
- patients with history of drug induced ITP
- patients with history of HCV, HBV and HIV infection.
- Patients who refuse to contribute in this study.
About this study
Prevalence of thyroid disorders in patients with immune thrombocytopenic purpura and its impact on treatment
Read the detailed description
We investigate patients with ITP for screening of thyroid disorders and how to deal with it and effect of this on the ttt
- Conditions
- Immune Thrombocytopenic Purpura, Thyroid Disorders
- Being tested
- Search for thyroid disorders, Laboratory test, Steroid and eltrombopage
- Medical subject headings
- Purpura, Thrombocytopenic, Idiopathic, Thyroid Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Search for thyroid disordersDiagnostic test
Also called Laboratory test
TSH , FT3 , FT4
Laboratory testDiagnostic test
Search for anti thyroid antibodies
Steroid and eltrombopageDrug
Also called Drugs used in ITP
See when we treat thyroid disorders, will patient respond to steroid or eltrombopage?
| Study group | Role | What they receive |
|---|---|---|
| Patients known ITP | Patients known ITP either newly diagnosed, chronic, refractory Age 18 yrs and above Patients with thyrodiectomy will not be in our study Receives: Diagnostic Test: Search for thyroid disorders; Diagnostic Test: Laboratory test; Drug: Steroid and eltrombopage |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assess the frequency of thyroid disorders in patients with IT
Screening of thyroid disorders in patients with ITP
Measured: Assess the frequency of thyroid disorders in patients with IT
Evaluate the treatment of thyroid disorders in improvement in platelets count.
Evaluate if patients have managed according to thyroid disorders, will this affect in their response to ITP management
Measured: Evaluate the treatment of thyroid disorders in improvement in platelets count.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2025
- Study startJul 2025 (estimated)
- Primary completion31 May 2026 (estimated)
- Study completion15 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Immune Thrombocytopenic PurpuraStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ayah Ibrahim Nemr, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07059910
- Sponsor's protocol ID
- ITP and thyroid disorders
- Status last verified
- Jul 2025
- First submitted
- 10 Jun 2025
- Last updated
- 17 Jul 2025
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment
- ClinicalTrials.gov ID
- NCT07059910
- Acronym / sponsor ID
- ITP and thyroid disorders
- Conditions
- Immune Thrombocytopenic Purpura, Thyroid Disorders
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Jul 2025 (estimated)
- Primary completion
- 31 May 2026 (estimated)
- Study completion
- 15 Aug 2026 (estimated)
- First posted
- 11 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prevalence of thyroid disorders in patients with immune thrombocytopenic purpura and its impact on treatment
Detailed description
We investigate patients with ITP for screening of thyroid disorders and how to deal with it and effect of this on the ttt
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients known ITP | – | Diagnostic Test: Search for thyroid disorders, Diagnostic Test: Laboratory test, Drug: Steroid and eltrombopagePatients known ITP either newly diagnosed, chronic, refractory Age 18 yrs and above Patients with thyrodiectomy will not be in our study |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- prospective cross sectional study
Key inclusion criteria (2 listed)
- ITP patients will be classified as newly diagnosed, persistent and chronic based on duration less than 3 months, 3-12 months, and more than 12 months respectively.
Key exclusion criteria (4 listed)
- patients with history of thyroidectomy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Search for thyroid disordersAlso: Laboratory testTSH , FT3 , FT4 | Diagnostic test | Patients known ITP |
| Laboratory testSearch for anti thyroid antibodies | Diagnostic test | Patients known ITP |
| Steroid and eltrombopageAlso: Drugs used in ITPSee when we treat thyroid disorders, will patient respond to steroid or eltrombopage? | Drug | Patients known ITP |
Primary outcome
Assess the frequency of thyroid disorders in patients with IT
Time frame: Assess the frequency of thyroid disorders in patients with IT
Screening of thyroid disorders in patients with ITP
Evaluate the treatment of thyroid disorders in improvement in platelets count.
Time frame: Evaluate the treatment of thyroid disorders in improvement in platelets count.
Evaluate if patients have managed according to thyroid disorders, will this affect in their response to ITP management
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2025.
Related trials for Immune Thrombocytopenic Purpura
RecruitingPhase 2
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
RecruitingPhase 1/2
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Immune Thrombocytopenia (ITP)
RecruitingPhase 3
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
RecruitingPhase 2
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Immune Thrombocytopenia
RecruitingPhase 3
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Immune Thrombocytopenic Purpura and Thyroid Disorders, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assess the frequency of thyroid disorders in patients with IT (time frame: Assess the frequency of thyroid disorders in patients with IT). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2025.